Company news

Cue Biopharma, Inc. news in 2024

Cue Biopharma, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 28, 2024

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 13, 2024

Cue Biopharma Announces Strategic Organizational Transition

November 13, 2024

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

November 7, 2024

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

October 3, 2024

Cue Biopharma Announces Proposed Public Offering

September 25, 2024

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

September 25, 2024

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

September 8, 2024

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 18, 2024

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

July 24, 2024

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

June 3, 2024

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

June 2, 2024

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

April 7, 2024

Calls in 2024

Decks in 2024